Pharmaceutical company Oramed Pharmaceuticals Inc (NASDAQ:ORMP) (TASE:ORMP) reported on Monday the receipt of approval from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for human trials of ORMD-0901 for the treatment of type 2 diabetes.
The company is currently developing the oral GLP-1 analog capsule (ORMD-0901). The Glucagon-like peptide (GLP-1) analogs, which mimic the natural GLP-1 hormone in the body, are used in the treatment of type 2 diabetes and currently only available via injection.
Under a prior Phase 1 study on type 2 diabetic patients, ORMD-0901 capsule was well tolerated and showed encouraging efficacy, including reducing blood sugar levels following a standard meal as compared to a placebo, added the company.
In conjunction, the company's proposed Phase 1 pharmacokinetic (PK) study is a fully-randomized, single-blind, placebo-controlled four way crossover study that will evaluate safety and the pharmacokinetics of ORMD-0901 compared to placebo and to open label Byetta, a GLP-1 analog, in up to 15 healthy subjects.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes